Conclusions
The study identified 164 ingredients and 58 intersection targets in GLNBD's treatment of PCM. Four key active compounds (quercetin, luteolin, fisetin, kaempferol) and four key proteins (ALB, EGFR, IL-6, VEGFA) were identified. Enrichment analysis revealed associations with negative regulation of apoptosis, response to hypoxia, positive regulation of transcription, and DNA-templated, with related pathways involving the pathway in cancer, phosphatidylinositol 3-kinase (PI3K) Akt signaling pathway, and AGE-RAGE signaling pathway in diabetic complications. Molecular docking validated stable binding activities between key target genes and essential active compounds, suggesting their potential role in modulating relevant pathways.
